A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|12|1011-1019

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.12, 2015-12, pp. : 1011-1019

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 5, 2015-05 ,pp. : 501-513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Variations in the Viral NS5B Region in Japanese Patients with Chronic Hepatitis C Virus Genotype 1b Infection

By  

Intervirology, Vol. 49, Iss. 6, 2006-10 ,pp. : 319-326

Karger

Access to resources Recommend Favorite

Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus

By  

HEPATOLOGY, Vol. 46, Iss. 5, 2007-11 ,pp. : 1341-1349

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite